Sarcoma

Sarcoma Robert Maki Oncologist 2001; 6: 333-337 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Appreciate the importance of STI571 (imatinib mesylate) in treating a subset of soft tissue sarcomas in adults. Learn about other investigational agents with promising activity in the treatment of soft tissue sarcomas in adults. Learn about approved agents with early evidence of activity in soft tissue sarcoma. Learn about ongoing clinical trials in soft tissue sarcoma, which may be appropriate for patient referral. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jul. 18, 2002 Most Recent Review: Jul. 18, 2003* Most Recent Update: Jul. 18, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.